Annals Internal Medicine, Author Interviews, Brigham & Women's - Harvard, Diabetes, Heart Disease / 07.06.2022
First-Line Treatment of Type 2 Diabetes: Cardiovascular Outcomes of SGLT-2 Inhibitors vs Metformin
MedicalResearch.com Interview with: HoJin Shin, BPharm, PhD Postdoctoral Research Fellow Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston, Massachusetts MedicalResearch.com: What is the background for this study? Response: The public health burden of cardiovascular disease has been increasing in people with diabetes along with the burden of diabetes itself.
- Cardiovascular disease affects approximately one-third of the population with type 2 diabetes and accounts for 50%–80% of their mortality
- 1 in 10 people in the US has diabetes